CONSHOHOCKEN, Pa., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the J.P. Morgan Annual Healthcare Conference on Monday, January 12, 2026 at 1:30pm PST. The presentation will be broadcast live and can be accessed here or by visiting Madrigal’s Investor Relations Events and Presentations page. A replay of the webcast will be available after the event. About MadrigalMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biophar ...

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the high short interest stocks to buy right now. On November 21, H.C. Wainwright raised the firm’s price target on Madrigal Pharmaceuticals to $620 from $568 and maintained a Buy rating. H.C. Wainwright increased its assumptions for Rezdiffra penetration after consulting with 6 key opinion leaders/KOLs. They reported real-world uptake of the drug among patients with metabolic dysfunction-associated steatohepatitis/MASH who have F2/F3 liver fibrosis. Des ...

They haven't peaked yet.Those who had the foresight to invest in Summit Therapeutics (SMMT 8.62%) and Madrigal Pharmaceuticals (MDGL 2.58%) three years ago are sitting pretty right now. Both companies have soared over this period, with the former skyrocketing 2,280% and the latter gaining 631%. These two rising stars in the biotech industry have experienced significant clinical and regulatory progress, which has fueled their growth engines. Even with these recent performances, Summit and Madrigal could have ...

Summary of Madrigal Pharmaceuticals FY Conference Call Company Overview - **Company**: Madrigal Pharmaceuticals (NasdaqGS:MDGL) - **Product**: Rezdiffra, a treatment for Metabolic Associated Steatotic Hepatitis (MASH) Key Points Financial Performance - Achieved a **$1 billion run rate** with **$287.3 million in sales** in the last quarter, indicating strong market uptake [2][20] - Over **10,000 prescribers** and **29,500 patients** on the drug, with a penetration rate of just under **10%** [2][20] - Projected revenue for **2026** is **$1.45 billion**, representing a **50% year-over-year growth** [26] Market Access and Payer Contracts - Secured favorable **payer contracting** for **2026**, ensuring first-line access with no step-throughs and improved utilization management criteria [3][20] - Gross-to-net discount expected to be in the **20%-30% range for 2025**, increasing to the **high 30% range for 2026** [21][22] Clinical Data and Product Efficacy - New data presented at the **AASLD conference** showed that discontinuation of Rezdiffra leads to a quick return of symptoms, emphasizing the need for chronic therapy [4][5] - Efficacy data from the **F4C population** showed a **decrease in liver stiffness of over 7 kPa**, providing confidence for the upcoming **MAESTRO-NASH outcomes study** in 2027 [6][8] Expansion into Endocrinology - Plans to expand focus from specialty GI and hepatologists to include **endocrinologists**, with a dedicated effort towards this specialty [10][12] - Approximately **2,000 high-target endocrinologists** have shown interest in prescribing Rezdiffra, indicating a potential market opportunity [12][13] Research and Development - Continued investment in **R&D** and **SG&A** to support the launch and pipeline development, with an increase in expenses expected [27] - The company is exploring **business development opportunities** to maintain leadership in the MASH space, including a recent deal for an oral GLP-1 asset [33][34] Future Outlook - The company believes it is at the beginning of a long growth trajectory, with significant unmet needs in the MASH market [41][42] - The potential for **multiple products** in the MASH category, with a strong pipeline and patent protection extending to **2045** [41][42] Additional Insights - The company has achieved **80% commercial coverage** within six months of launch, indicating strong market access [31] - There is a focus on maintaining excellent access for patients while navigating the complexities of payer contracts [20][21] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting Madrigal Pharmaceuticals' strong market position and future growth potential in the MASH treatment landscape.

Madrigal Pharmaceuticals (NasdaqGS:MDGL) FY Conference December 02, 2025 04:15 PM ET Company ParticipantsBill Sibold - CEOMardi Dier - CFOConference Call ParticipantsMike DiFiore - AnalystMike DiFioreLet's get started.Bill SiboldLet's get started.Mike DiFioreBut welcome, everybody. Those of you who don't know me, I'm Mike DiFiore. I'm one of the biotech analysts covering Madrigal and Evercore. But pleasure to have the management team from Madrigal here. Bill, Mardi, welcome. Thanks so much for making it dow ...

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities hit a record high in the third quarter, fueled by continued gains in technology and falling bond yields. Easing tariff rhetoric and renewed AI infrastructure investments boosted large tech stocks. In mid-September U.S. Federal Reserve lowered rates by 25 basis points. Against this backdrop, the fund returned -1.78% (net) compared to the ...

Core Insights - Madrigal Pharmaceuticals, Inc. focuses on developing treatments for metabolic dysfunction-associated steatohepatitis (MASH) and is recognized for its innovative approach to liver-related diseases [1] - H.C. Wainwright has set a price target of $620 for MDGL, indicating a potential increase of approximately 10.99% from its current price of $558.61 [1][5] Company Developments - Recently, the company granted equity awards to three new non-executive employees as part of its 2025 Inducement Plan, which was approved by the independent Compensation Committee [2] - The equity awards include 2,125 time-based restricted stock units that will vest over four years, aimed at attracting and retaining talent [2] Stock Performance - MDGL is currently trading at $563.96, reflecting a 4.03% rise with a price increase of $21.84 [3][5] - The stock has shown volatility, with a trading range between $535 and $564.90 on the current day, and over the past year, it has seen a high of $577.90 and a low of $265 [3] - The company's market capitalization is approximately $12.51 billion, indicating its substantial presence in the biopharmaceutical sector [4]

Core Insights - H.C. Wainwright upgraded Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to a "Buy" rating and increased its price target from $568 to $620, reflecting confidence in the company's future performance [1][5] - The current stock price of MDGL is $559.40, showing a 3.19% increase, indicating strong investor interest and market activity [3][5] - Madrigal's market capitalization is approximately $12.41 billion, highlighting its significant presence in the biopharmaceutical sector [4] Company Developments - Madrigal Pharmaceuticals granted equity awards to new non-executive employees as part of its 2025 Inducement Plan, which includes 2,125 restricted stock units designed to attract talent and ensure employee retention [2][5] - The stock has fluctuated between $535 and $563.50 today, with a yearly high of $577.90 and a low of $265, reflecting its volatility and growth potential [3]

Core Insights - Madrigal is experiencing an exciting year with significant opportunities in the market due to high unmet needs for patient solutions [2] - The company has successfully launched Rezdiffra, overcoming previous industry failures to find a viable product [2] - Madrigal is building a pipeline that includes an Oral GLP-1 aimed at enhancing Rezdiffra through a fixed-dose combination [3] Company Overview - Madrigal has assembled a highly skilled team, described as the best the CEO has ever worked with, to drive the company's initiatives [3] - The company is currently in the launch phase of Rezdiffra, which is characterized as an outstanding launch [3] Market Context - There has been a historical struggle in the industry, with over 20 failed attempts to find a solution for the unmet needs in the market [2] - The successful development of Rezdiffra positions Madrigal uniquely in a market that has seen significant challenges [2]

Summary of Madrigal Pharmaceuticals Conference Call Company Overview - **Company**: Madrigal Pharmaceuticals (NasdaqGS:MDGL) - **Product**: Rezdiffra, a treatment for MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease) Key Industry Insights - **Market Opportunity**: There is a significant unmet need in the MASH market, with over 20 failed attempts by the industry to find a solution before Madrigal's success with Rezdiffra [2][3] - **Patient Population**: The diagnosed patient population in the U.S. is approximately 1.5 million, with the F2 and F3 indications accounting for about 525,000 patients. The target prescriber base is narrowed down to 14,000, leading to an actionable patient population of 315,000 [6][7] - **Current Treatment Penetration**: Currently, only about 10% of the identified patient population is being treated, indicating substantial growth potential [6][7] Product and Pipeline Development - **Rezdiffra's Profile**: The product is positioned as a foundational therapy for MASH, with a once-a-day oral dosage that is effective and well-tolerated, which is considered a "holy grail" in the industry [11] - **Sales Forecast**: Initial sales in 2024 are projected to be under $200 million, but the potential market size for Rezdiffra could reach $5 billion to $10 billion as penetration increases [3][12][15] - **Intellectual Property**: Madrigal has secured intellectual property for Rezdiffra until 2045, allowing ample time for market development [3] Competitive Landscape - **Comparison with Competitors**: Madrigal's focused approach contrasts with competitors like Novo, which have multiple indications and broader product lines. Madrigal's strategy is to engage directly with specialists, enhancing their market presence [18][19] - **Market Dynamics**: The company is observing the market entry of competitors and is prepared to adapt its strategy accordingly. The focus remains on building a strong presence in the specialty market [19][20] Sales and Marketing Strategy - **Adoption Rates**: Initial adoption rates in specialty clinics are reported to be as high as 80%, attributed to effective white-glove service and support for prescribers [21][24] - **Patient Adherence**: The persistence rate for patients on Rezdiffra is reported to be around 90% at the 12-month mark, significantly higher than the industry benchmark of 60-70% for well-tolerated oral medications [24][25] - **Sales Force Strategy**: The company has built a dedicated sales force to educate and support prescribers, which is crucial for navigating the complexities of specialty drug prescriptions [22][23] Financial Projections - **Gross Unit Projections**: For 2026, Madrigal anticipates gross unit sales to be in the high 30s percentage range, with a disciplined approach to contracting with commercial payers [29][30] - **Market Mix**: The revenue mix is expected to be 50-55% from commercial payers, 30-35% from Medicare, and the remainder from Medicaid and government sources [34] Research and Development - **Ongoing Studies**: The Maestro Outcomes study is ongoing, focusing on F4 cirrhosis patients, with confidence in positive outcomes based on previous open-label trial results [45][46] - **Patient Enrollment Criteria**: The study is designed to enroll patients with specific platelet counts, differentiating it from other ongoing studies that may include less severe populations [48][49] Conclusion - **Long-term Vision**: Madrigal aims to maintain its leadership in the MASH market for decades, supported by a robust pipeline and a strong foundational product in Rezdiffra [15][16]